Midterm Results of Endovascular Treatment of Superficial Femoral Artery Disease with Biodegradable Stents: Single-Center Experience

Silingardi, Roberto; Lauricella, Antonio; Coppi, Giovanni; Nicolosi, Emanuele; Gennai, Stefano

doi:10.1016/j.jvir.2014.10.050

Cited by 8 publications

(19 citation statements)

References 22 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whereas most medical implant materials that are presently in use are long‐lived, for temporary applications biodegradable materials could be advantageous to limit side effects. While degradable polymeric wound suture filaments are clinically established, corrodible magnesium alloys could provide the required strength for load‐bearing applications in bone repair or as vascular stents . After implantation magnesium corrodes by reacting with water molecules and the primary corrosion products are hydrogen gas, magnesium ions, and hydroxide ions.…”

Section: Introductionmentioning

confidence: 99%

“…While degradable polymeric wound suture filaments are clinically established, corrodible magnesium alloys could provide the required strength for load-bearing applications in bone repair or as vascular stents. [1][2][3][4][5][6][7] After implantation magnesium corrodes by reacting with water molecules and the primary corrosion products are hydrogen gas, magnesium ions, and hydroxide ions. When the production exceeds the diffusion rate hydrogen gas can accumulate in tissue cavities while soluble ions together with other molecules from the physiological environment can form precipitates that result in a protective, biocompatible corrosion layer on implant surfaces.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Susceptibility of metallic magnesium implants to bacterial biofilm infections

Rahim

Rohde

Rais

et al. 2016

J Biomedical Materials Res

View full text Add to dashboard Cite

Magnesium alloys have promising mechanical and biological properties as biodegradable medical implant materials for temporary applications during bone healing or as vascular stents. Whereas conventional implants are prone to colonization by treatment resistant microbial biofilms in which bacteria are embedded in a protective matrix, magnesium alloys have been reported to act antibacterial in vitro. To permit a basic assessment of antibacterial properties of implant materials in vivo an economic but robust animal model was established. Subcutaneous magnesium implants were inoculated with bacteria in a mouse model. Contrary to the expectations, bacterial activity was enhanced and prolonged in the presence of magnesium implants. Systemic antibiotic treatments were remarkably ineffective, which is a typical property of bacterial biofilms. Biofilm formation was further supported by electron microscopic analyses that revealed highly dense bacterial populations and evidence for the presence of extracellular matrix material. Bacterial agglomerates could be detected not only on the implant surface but also at a limited distance in the peri-implant tissue. Therefore, precautions may be necessary to minimize risks of metallic magnesium-containing implants in prospective clinical applications. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 1489-1499, 2016.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Susceptibility of metallic magnesium implants to bacterial biofilm infections

Rahim

Rohde

Rais

et al. 2016

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

“…On subsequent screening and critical appraisal of the remaining articles, six articles and one conference abstract were included in this review. These included two RCTs, 12,13 two prospective cohort studies, 14,15 one retrospective cohort study, 16 one pilot study, 17 and one conference abstract. 18 An additional four conference abstracts [19][20][21][22] and one pilot study 23 were included after reference checking, making a total of seven published studies and five conference abstracts.…”

Section: Resultsmentioning

confidence: 99%

Current status and future perspectives of bioresorbable stents in peripheral arterial disease

Haelst

Weem

Moll

et al. 2016

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

“…9 The 2-year primary patency rates were between 84% 8 and 77%. 12 The rates of TLR at 1-year follow-up were between 8.8% 8 and 57.1%. 9…”

mentioning

confidence: 96%

“…[4][5][6][7] BVS have thus far been tested in 160 patients with symptomatic PAD due to external iliac, common femoral, and femoropopliteal arterial obstructions. [8][9][10][11][12] The 1-year primary patency rates ranged widely between 88% (PLLA with drug elution) 8 and 32% (PLLA without drug elution). 9 The 2-year primary patency rates were between 84% 8 and 77%.…”

mentioning

confidence: 99%

Commentary: Bioresorbable Drug-Eluting Scaffold for Peripheral Artery Disease: The Best of Two Worlds or Unnecessary?

Lämmer

2020

J Endovasc Ther

View full text Add to dashboard Cite

Bioresorbable vascular scaffolds (BVS) were developed in the 1990s and have been in testing ever since. 1 Tamai et al 2 reported the first human use in coronary arteries in 2000. The first use in peripheral artery disease (PAD) was reported in 2009 3 using a biodegradable magnesium stent; however, poly-l-lactic acid (PLLA) has been the backbone of most endovascular scaffolds.In the August 2020 issue of the JEVT, Kum et al 4 report a single-center, retrospective study focusing on 41 patients from the DISAPEAR (Drug Impregnated Bioresorbable Stent in Asian Population Extremity Arterial Revascularization) Registry with chronic limb-threatening ischemia (CLTI) due to de novo infrapopliteal lesions. All patients were in the advanced Rutherford categories 5 and 6, 90% were diabetic, and a quarter had severe vessel wall calcification, making it a challenging group of patients. The study device was the balloon-expandable Absorb BVS (Abbott Vascular, Santa Clara, CA, USA) developed for the coronary arteries. Its PLLA scaffold is coated with a polymer [poly(d-l-lactide)] that elutes the antiproliferative drug everolimus. The device was implanted without complications in 53 lesions. The median radiological follow-up by duplex ultrasound examination was 23 months (maximum 4 years). Angiography was performed only on suspicion of a clinically relevant restenosis. Clinical follow-up was performed at least monthly until complete wound healing occurred.The 86% 12-month per-scaffold patency rate was somewhat lower compared with the 92% to 96% patency rates in previous BVS studies, [5][6][7] but this study did include a group of patients with advanced CLTI. Freedom from imagingdefined occlusion and clinically-driven target lesion revascularization (TLR) estimates at 12 months were both 93%. Freedom from major amputation was 98% after 1 year. Wound healing was achieved in 24 of the 39 Rutherford category 5/6 patients (62%) at 6 months and in 31 patients (79%) at 12 months, which compares well with other BVS studies (64% at 1 year). 6 Median time to wound healing was 4 months.

show abstract

Midterm Results of Endovascular Treatment of Superficial Femoral Artery Disease with Biodegradable Stents: Single-Center Experience

Cited by 8 publications

References 22 publications

Susceptibility of metallic magnesium implants to bacterial biofilm infections

Susceptibility of metallic magnesium implants to bacterial biofilm infections

Current status and future perspectives of bioresorbable stents in peripheral arterial disease

Commentary: Bioresorbable Drug-Eluting Scaffold for Peripheral Artery Disease: The Best of Two Worlds or Unnecessary?

Contact Info

Product

Resources

About